{"id":"placebo-human-albumin-2-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypervolemia"},{"rate":null,"effect":"Pulmonary edema"},{"rate":"rare","effect":"Allergic reaction"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo: Human albumin 2.5%","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:59:38.203988+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:59:43.806921+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo: Human albumin 2.5%","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:59:44.183678+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bilirubin sequestering agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:59:56.522849+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201451/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:59:56.095217+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Human albumin is a naturally occurring plasma protein that increases and maintains intravascular oncotic pressure, helping to retain fluid in the vascular space and prevent fluid shifts into the interstitium. It also serves as a carrier protein for various endogenous and exogenous substances. The 2.5% concentration is a hypotonic or isotonic formulation used for volume replacement in conditions involving significant fluid loss or hypoproteinemia.","oneSentence":"Human albumin 2.5% acts as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:04.987Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:59:57.808975+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Hypovolemia and shock (hemorrhagic, septic, or traumatic)"},{"name":"Hypoproteinemia and edema management"},{"name":"Plasma volume expansion during major surgery or critical illness"}]},"trialDetails":[{"nctId":"NCT00936819","phase":"PHASE2","title":"The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2013-07-19","conditions":"Anterior Wall Myocardial Infarction","enrollment":47},{"nctId":"NCT04061746","phase":"PHASE1","title":"Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2020-02-27","conditions":"Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT01745783","phase":"PHASE1, PHASE2","title":"Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis","status":"COMPLETED","sponsor":"Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud","startDate":"2013-01","conditions":"Multiple Sclerosis","enrollment":26},{"nctId":"NCT03656198","phase":"PHASE4","title":"Non-specific Effects of Rabies Vaccine","status":"COMPLETED","sponsor":"Ross University School of Veterinary Medicine","startDate":"2018-08-29","conditions":"Influenza-like Illness, Upper Respiratory Disease, Diarrhea","enrollment":546},{"nctId":"NCT01651351","phase":"PHASE4","title":"GLASSIA Infusion Rate Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2012-07-31","conditions":"Alpha1-antitrypsin Deficiency, Healthy Volunteers","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1201451"},"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo: Human albumin 2.5%","genericName":"Placebo: Human albumin 2.5%","companyName":"Baxalta now part of Shire","companyId":"baxalta-now-part-of-shire","modality":"Biologic","firstApprovalDate":"","aiSummary":"Human albumin 2.5% acts as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure. Used for Hypovolemia and shock (hemorrhagic, septic, or traumatic), Hypoproteinemia and edema management, Plasma volume expansion during major surgery or critical illness.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:59:57.808975+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}